However, these medications, classified as GLP-1 receptor agonists (for Semaglutide) and dual GLP-1/GIP receptor agonists (for Tirzepatide), are now being explored for a variety of other potential health benefits beyond their established uses including: improving cardiovascular health, exerting neuroprotective effects, exhibiting anti-inflammatory properties, ad potentially benefitting conditions such as polycystic ovary syndrome (PCOS) and chronic kidney disease
Compounded medications offered through bmiMD are produced in FDA-registered facilities but are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality
Patients often report a more reliable and satisfactory experience with Semaglutide
Moreover, our focus was solely on the impact of different routes of administration on adverse events (AEs), without excluding other confounding factors such as adherence to prescribed administration schedules or dosages, which could potentially influence (AEs)
According to the American Diabetes Association's Standards of Care, GLP-1 RAs with proven cardiovascular benefit, such as semaglutide, may be considered as first-line therapy in patients with type 2 diabetes who have established atherosclerotic cardiovascular disease or high cardiovascular risk, independent of metformin use
Partial Data by Infogroup 2026